There is growing interest in the role of matrix metalloproteinases in vascular diseases. These conditions are often characterized by excessive tissue remodelling, and increased matrix metalloproteinase activity has been demonstrated in aneurysms, intimal hyperplasia and atherosclerotic plaque disruption. These enzymes represent a potential target for therapeutic intervention to modify vascular pathology.
Introduction
Vascular diseases account for the majority of deaths and disability in Western countries and are the consequence of years of vascular connective tissue remodelling. Connective tissue integrity depends upon a balance between degradation and repair of the extracellular matrix (ECM). The activity of proteolytic enzymes is the rate-limiting step in ECM degradation. 1 It is now well established that, among numerous potential proteinases, the matrix metalloproteinases (MMPs) play the major role in the degradation of collagen and other ECM macromolecules.
Expressed at low levels in normal adult tissue, MMPs are up-regulated in normal and pathological remodelling processes. They play a key role in processes such as wound healing, 2 but there is growing interest in a role in disease states where ECM breakdown is a dominant feature. Early interest focused on a pathological role for MMPs in the resorption of periodontal structures in periodontal disease, 3 the destruction of joints in rheumatoid arthritis, 4 and the local invasive behaviour of malignancies. 5 There is a growing body of evidence supporting a pivotal role for MMPs in vascular disease, particularly aneurysm formation, intimal hyperplasia and atherosclerosis, which have led to the study of MMP inhibition in models of vascular disease.
site. There are more than 20 members of the family, which exhibit structural homology, but each of which is the product of a different gene. All members of the MMP family degrade one or more components of the ECM. They are secreted in latent pro-enzyme forms that require activation for proteolysis, which in turn is controlled by speci c tissue inhibitors of metalloproteinases (TIMPs).
The MMPs have been subdivided into four major subclasses: collagenases (MMPs 1, 8, 13, 18) ; gelatinases (MMP-2, MMP-9); stromelysins (MMPs 3, 10, 11, 19, 20) ; and membrane-type MMPs or MT-MMPs ( MMPs 14, 15, 16, 17) . The early classi cation of MMPs was based upon substrate speci city as shown in Table 1 , though many are now recognized to have broad and overlapping substrate speci cities.
Evolution of the MMP family from a single prototype has led to conservation of the same basic ve-domain structure, with 70% similarity between members of the same group and 50% similarity between members of different groups (Figure 1 ). 6 The rst (signal) domain is essential for secretion of the peptide from the cell. The propeptide domain incorporates the 'cysteine switch' mechanism, highly conserved throughout the MMP family, which is essential for maintenance of the inactive zymogen form. 7 The catalytic domain forms the putative tridentate catalytic zinc binding site. 8 The hinge region is a small proline-rich domain thought to allow folding of the c-terminal domain on to the catalytic domain, while the function of the nal domain is unclear.
MMPs are expressed in normal tissues. MMP-2 is the most commonly expressed enzyme in normal adult tissues, though limited to stromal cells. 9 MMP-9 is expressed by haematopoietic cells 1 0 whilst MMP-7 is found in the glandular epithelial cells of the gastrointestinal tract and endometrium. 1 1 MMP-7 is also found in neoplastic cells, 1 2 along with MT-MMPs on the tumour cell membrane. 1 3 Most work on tumour tissue has shown that stromal cells Table 1 The major MMP subtypes and their substrates. Collagenases  MMP-1  Interstitial collagenase  Collagens I, II, III, VII, VIII, X, gelatin, aggrecan, MMPs 2 and 9  MMP-8  Neutrophil collagenase  Collagens I, II, III, V, VII, VIII, X, gelatin, aggrecan  MMP-13  Collagenase-3  Collagens I, II, III, IV, gelatin, aggrecan, PAI2  MMP-18 Xenopus collagenase Collagen I Gelatinases MMP-2 Gelatinase A (72 kDa gelatinase) Gelatin, collagens I, IV, V, VII, X, XI, XIV, elastin, bronectin, aggrecan MMP- 9 Gelatinase B (92 kDa gelatinase) Gelatin, collagen types IV, V, VII, X, elastin
MMP Enzyme Principal known substrates

Stromelysins
MMP-3
Stromelysin-1 Collagens III, IV, IX, X, gelatin, aggrecan, MMPs 1, 7, 8, 9, Stromelysin-2 Collagens III, IV, V, gelatin, casein, MMPs 1 and 8 MMP- 11 Stromelysin-3
MMP-7
Matrilysin (PUMP-1) Collagens IV, X, gelatin, bronectin MMP- 12 Macrophage metalloelastase Collagen IV, gelatin, elastin, bronectin rather than tumour cells predominantly express both the gelatinases and stromelysins. 1 4 The control of MMP activity The activity of MMPs is tightly regulated at both an intraand extra-cellular level. Many growth factors, cytokines, hormones and tumour promoters regulate MMP expression at the transcriptional level and a number of nuclear binding sites have been identi ed in the gene promoters. IL-1, PDGF and TNF-a have all been shown to have a stimulatory effect, whilst others such as heparin, TGF-b and corticosteroids have an inhibitory effect. 1 5 The second level of control of the MMPs is the extracellular activation of the secreted latent pro-enzymes. This is likely to be a crucial step in terms of their biological behaviour in disease states, since activation may tip the bal-Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] ance in favour of matrix degradation. Activation occurs by cleavage of the pro-peptide, leading to a conformational change in the enzyme structure involving the cysteine switch mechanism.
Membrane-type MMPs
The major physiological activator of the MMPs is plasmin. The binding and activation of urokinase plasminogen activator (uPA) by its cell surface receptor is thought to localize proteolytic activity to the leading edge of the cell. 1 6 uPA and its receptors are expressed by a variety of cells including those intimately involved in processes of tissue remodelling, especially macrophages. Inhibition of uPA prevents matrix degradation in vitro. 1 7 The subsequent stages of activation form a similar positive feedback loop to the clotting cascade whereby plasmin activates MMP-1, MMP-3 and MMP-9 directly, then active MMP-3 further activates MMP-1, and active MMP-1 cleaves pro-MMP-9. 1 8 The action of MMP-3 upon MMP-1 leads to a ve to eightfold increase in proteolytic activity. Plasminogen activator inhibitor (PAI) has an inhibitory effect upon uPA, down-regulating the activation cascade, and the balance between the two may be important in determining the overall level of proteolytic activity. 1 5 The major physiological activator of MMP-2 is now recognized to be a member of the MT-MMP family, MT1-MMP. 1 9 At least six members of the MT-MMP family have been identi ed. 2 0 A speci c interaction between MMP-2 and TIMP-2 is a prerequisite to binding and subsequent activation of MMP-2 by MT1-MMP. MMP-2 and MMP-9 activity are increased by reactive oxygen species produced by macrophage-derived foam cells, 2 1 which may be important in understanding the role of MMPs in atherosclerosis. 2 2 The action of TIMPs The third regulatory mechanism involves the binding of the active MMP to TIMPs, and less speci cally by a 2 -macroglobulin. The TIMP family includes at least ve members. Although structurally similar, the TIMPs only share 37-42% amino acid identity, but are to an extent interchangeable in their ability to inhibit MMPs. TIMPs inhibit MMPs by binding irreversibly to the active form of the enzyme in a 1:1 molar ratio. 2 3 The net level of proteolytic activity is thus dependent upon the relative concentrations of the active enzymes and their inhibitors.
TIMP-1 is particularly important in the regulation of MMP-9 activity, and TIMP-2 is crucial for the control of MMP-2 activity as discussed previously. TIMP-3 is the only TIMP recognized to bind rmly to the ECM, localizing MMP inhibition to the ECM. Of particular interest and in contrast to TIMP-1 and TIMP-2, TIMP-3 can initiate cellular apoptosis. 2 4 Overexpression may induce vascular smooth muscle cell apoptosis and may play a role in atherosclerosis. 2 5 
MMPs in aneurysmal disease
Pathophysiology Aneurysmal disease is characterized by extensive medial degeneration with loss of elastin, 2 6 apoptosis, reduced numbers of smooth muscle cells 2 7 and in ammatory in ltration consisting of T-cells, B-cells and macrophages. 2 8 In ammation and excessive breakdown of the ECM have been identi ed as the cause of destruction of the arterial wall. 2 9 The most important structural elements of the aortic wall are collagen types I and III and elastin. Collagen bres are arranged in such a way that, while normally extremely resistant to stretch, the vessel is elastic with the main load placed upon the elastin bres. 3 0 Elastin degradation is thought to initiate the arterial expansion, while loss of brillar collagen predisposes to aneurysm rupture. 3 1 The loss of elastin is a striking histological feature of the aneurysm wall, representing only 8% of the dry weight compared to 35% of non-aneurysmal aorta. 3 2 Infusion of elastase in animal and in vitro human models leads to aneurysm formation, intense in ammatory in ltration, loss of medial elastin and the overproduction of proteolytic enzymes. 3 3 -3 6 Furthermore, diseases such as Marfan's and Ehlers-Danlos type IV disease exhibit mutations in genes encoding type Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] III collagen and brillin-I, an elastic bre component, predisposing individuals to aneurysm formation. 3 7 Interestingly, the collagen content of aneurysms increases with size. 3 8 ,3 9 This is thought to be a compensatory mechanism to increased wall stretch 4 0 since this is known to stimulate matrix synthesis by smooth muscle cells in vitro. 4 1 Procollagen expression is signi cantly increased compared to non-aneurysmal tissue. 4 2 It seems likely that a combination of increased collagen synthesis with elastin degradation combine to alter the matrix structure of the vessel wall in aneurysms, 4 3 with eventual failure of both contributing to rupture.
The role of MMPs
Interest in the role of proteolytic enzymes in aneurysm development has grown considerably since the rst reports by Campa and Busuttil in the 1980s. 3 2 ,4 4 They described an increase in elastase and collagenase activity within aneurysmal tissue and identi ed a 90-kDa elastase of the MMP family, now recognized as MMP-9. Vine and Powell reported an increase in gelatinolytic activity, associated with a spectrum of enzymes of molecular weights ranging from 55 to 92 kDa. 4 5 They also detected stromelysin and collagenase activity, though the levels were relatively small. Brophy published similar results regarding gelatinolytic activity in aneurysmal tissue in the same year. 4 6 Irizarry et al reported increased levels of MMP-1 in extracts of aortic aneurysm compared with normal aorta using immunoblotting. 4 7 Tissue extracts from aneurysms exhibiting high levels of gelatinase activity are capable of degrading elastin in tissue sections of human aorta. 4 8 Subsequent studies have conrmed that the high levels of elastolytic activity represent a combination of increased levels of MMP-2 4 9 and MMP-9, 5 0 ,5 1 both of which degrade elastin; the former being the more potent enzyme in this regard. 5 2 Thompson and coworkers demonstrated a 10-fold increase in the level of MMP-9 in human aortic aneurysm tissue compared with normal controls, and localized the expression to macrophages. 5 1 Further work by the same group studied the level of MMP and TIMP mRNA expression using competitive polymerase chain reaction. 5 3 They identi ed a signi cant increase in the expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 mRNA in aneurysms compared with normal aorta, but also a signi cant increase in the ratio between enzyme and inhibitor in aneurysms, suggesting a potential imbalance leading to increased proteolysis. The predominant enzyme was MMP-9, with mRNA levels 20 times and twice higher than MMP-1 and MMP-2 respectively. Similar results were obtained by Knox who demonstrated a signicant increase in the ratio between MMP-2 and TIMP-2 in aneurysm compared with normal aorta. 5 4 This hypothesis has been studied further in vitro. When monocytes were cultured with aortic explants, they in ltrated the tissue, produced MMP-9 and initiated proteolytic destruction of the elastin component. 5 5 This phenomenon was prevented by the addition of MMP-9 inhibitors. Others have demonstrated high levels of MMP-9 in aneurysmal aorta, predominantly localizing to macrophages, 5 6 ,5 7 and in contradistinction to normal tissue, signi cant proportions of MMP-2 and MMP-9 are found in the active forms. 5 8 Smooth muscle cells may also play a role in enzyme production. Cultured medial smooth muscle cells from ane-urysmal tissue produced signi cantly higher levels of both MMP-2 and MMP-9 than control cells. 5 9 ,6 0 MMP activation by plasmin has been identi ed as an important factor in aneurysm development. 6 1 Davis and colleagues studied MMP-2 and MMP-9 activity and expression in human aortic tissue from patients undergoing bypass surgery for aneurysms or occlusive disease and compared them with non-diseased tissue from organ donors. 6 2 The level of MMP-9 was signi cantly higher in both aneurysmal and occlusive disease compared with controls, but with little difference between the aneurysm and occlusive groups. The predominant source of the enzyme was macrophages. In contrast, the level of MMP-2 was signi cantly higher in aneurysms compared with both normal aorta and occlusive disease, with mesenchymal cells forming the primary source of enzyme.
There is mounting evidence to suggest a systemic increase in mesenchymal MMP-2 expression as shown by the development of vein graft aneurysms in patients with aneurysmal disease elsewhere, 6 3 and increased MMP-2 expression in venous tissue from patients with aneurysms compared with patients without aneurysms. 6 4 As discussed previously, MT1-MMP is involved in the processing of the MMP-2 pro-enzyme. MT1-MMP is expressed in the aneurysm wall by both macrophages and smooth muscle cells in a similar pattern to MMP-2. This indicates a broader distribution of expression than in occlusive disease and potentially a different role in the control of matrix degradation between the two degenerative aortic diseases. 6 5 Though the interaction between smooth muscle cells and in ammatory cells and their relative importance in aneurysmal disease requires clari cation, it seems likely that both are intricately involved in the proteolytic cascade leading to tissue degradation.
Whilst the gelatinases seem to be the most important MMPs with regard to elastolysis in aneurysm pathogenesis, there is increasing evidence linking other members of the family to the disease. MMP-8, identi ed within atherosclerotic disease and produced by macrophages, has also been identi ed in aneurysms. 6 5 MMP-12, also initially identi ed in occlusive disease, was expressed in complex aneurysmal aortic lesions in apo-E de cient mice. 6 1 More importantly, recent work identi ed MMP-12 in human aneurysmal tissue, expressed by in ltrating macrophages and localized to fragmented aortic elastin products. 6 6 This pattern is distinct from other elastolytic enzymes and suggests a particularly important role in matrix degeneration. The level of MMP-12 was seven times higher than normal aorta. However, recent work with knockout mice suggests that MMP-9 rather than MMP-12 plays the more critical role in aneurysm development. 6 7 MMP-13, a collagenase with limited tissue distribution and a tightly regulated pattern of expression, has been identi ed in human aortic aneurysms. 6 8 Using RT-PCR and Southern blots, MMP-13 was detected in both aneurysmal tissue and occlusive disease but not normal control tissue, with a higher level of expression in aneurysmal tissue compared to atherosclerotic aorta. MMP-13 was localized to smooth muscle cells which, when isolated and cultured, continued to express mRNA for MMP-13 in vitro. MMP-3 has been identi ed within aneurysms and cultured aneurysmal smooth muscle cells. 5 0 , 6 9 The role of MMP-3 in ane-Vascular Medicine 2002; 7: 117-133 urysm pathogenesis is unclear, though it may be important through the activation of MMP-1. 7 0 Early data suggested a decrease in the level of TIMPs in aneurysms, 7 1 which was not con rmed in subsequent studies. 7 2 Indeed, many studies have shown the opposite to be true, with increased levels of TIMP-1 being demonstrated. 5 1 ,5 6 Despite this, local overexpression of TIMP-1 by transfection of TIMP-1 DNA to smooth muscle cells in a rat model of aneurysmal disease prevented rupture 7 3 and a variant in the TIMP-2 coding sequence has been associated with the identi cation of aneurysms in humans. 7 4 Systemic MMP levels While the majority of work regarding MMP-2 and MMP-9 has focused upon the abdominal aorta, increased proteolysis may be a systemic phenomenon. Recent studies have shown an association between serum MMP-2 levels and the occurrence of cerebral aneurysms. 7 5 Interestingly, an association has also been made between the development of intracranial aneurysms and a functional polymorphism in the MMP-9 promoter region, possibly leading to variability in expression at the level of transcription. 7 6 The plasma level of MMP-9 is increased in patients with abdominal aortic aneurysms. 7 7 Furthermore, the level in those patients with multiple aneurysms was signi cantly higher than in those with isolated aortic aneurysms. It is unclear whether the aneurysms represented the source of MMP-9 and the relationship between these observations and aneurysm pathogenesis requires clari cation.
Summary
In summary, numerous studies have provided evidence that MMPs, particularly those with elastolytic and collagenolytic activity, are important molecular participants in aneurysm pathogenesis. However, their precise roles and the potential for pharmacological intervention will require further clari cation. The reasons why certain individuals should be prone to matrix degeneration and aneurysm formation remain elusive, and the pathogenesis is certainly multifactorial. 7 8 There is a genetic component, since rst degree relatives of individuals with aneurysms are at an increased risk independent of other known cardiovascular risk factors. 7 9,8 0 Smoking is the single largest environmental risk factor, others include hyperlipidaemia and hypertension, but their precise role remains unclear. A better understanding of the interaction between in ammatory cells and mesenchymal cells within the arterial wall should allow identication of speci c genetic risk factors which predispose to aneurysm development.
MMPs in intimal hyperplasia
Pathophysiology Intimal hyperplasia is characterized by the migration and proliferation of smooth muscle cells with subsequent accumulation of ECM, producing luminal narrowing. Occurring between the endothelium and the internal elastic lamina in arteries or between the endothelium and medial smooth muscle cells in vein grafts, intimal hyperplasia has distinct hyperacute, acute and chronic phases. 8 1 Endothelial cell damage triggers a complex series of events leading to a phenotypic change in smooth muscle cells, from a contractile to secretory role. 8 2 These cells undergo a period of proliferation and migration from the media to the intima where they undergo a second proliferative phase, followed by a quiescent stage of matrix synthesis. These changes are responsible for the majority of late failures following bypass grafting, 8 3 angioplasty 8 4 and endarterectomy. 8 5 ,8 6 Much of our understanding of intimal hyperplasia has been gained from animal models of vascular injury. 8 7 Intimal injury leads to denudation of the endothelium, and medial necrosis and recovery can take up to 12 weeks. Up to 25% of the innermost medial smooth muscle cells are lost following injury but cellular proliferation starts within 48 hours, returning to normal levels after approximately 4 weeks. Meanwhile, endothelial regeneration is initiated from the undamaged ends. Migration of smooth muscle cells from the media to the intima occurs 4 days following injury, and upon reaching the intima they undergo further proliferation. The excess proliferation probably represents an exaggeration of the normal healing response, largely regulated by growth factors such as basic broblast growth factor (bFGF) and PDGF, which control smooth muscle cell replication and migration respectively. 8 8 ,8 9 The role of MMPs The breaching of the basement membrane by migrating smooth muscle cells to reach the intima appears to be the rate-limiting step in intimal hyperplasia. There is mounting evidence that MMPs control this stage of the process and are intricately involved in the pathogenesis of stenoses through their expression by smooth muscle cells. Intimal hyperplasia in vein grafts may be due in part to injury to the vein at the time of harvest. Surgical preparative injury has been shown to induce phenotypic modulation of a subtype of smooth muscle cells to a synthetic phenotype and increase MMP activity. 9 0 In vitro models have been used to demonstrate increased smooth muscle cell expression of collagenase and stromelysin genes following mechanical injury, 9 1 and this is now supported by work in animal models. In studies of the rat carotid artery, there was constitutive expression of MMP-2 and a marked increase in activity between 4 and 14 days after arterial injury. 9 2 MMP-9 expression was also increased but this occurred early after injury, peaking at 3 days. Administration of an MMP inhibitor resulted in a 97% reduction in smooth muscle cell migration. The authors suggested that active MMP-9 might be controlling migration of smooth muscle cells from media to intima. In contrast, mature human restenotic lesions with abundant extracellular matrix exhibit reduced MMP activity and increased levels of TIMP-1 compared with both normal artery wall and atherosclerotic lesions. 9 3 Studies in a pig model of arterial injury revealed a similar response, with MMP-9 induced to a peak at 3 days and MMP-2 at 7 days, though levels remained elevated until 21 days. 9 4 Expression was localized to medial smooth muscle cells, particularly around areas of injury-induced necrosis. In this model, the up-regulation of MMP production paralleled the time course of smooth muscle cell migration and proliferation. Use of vein as carotid interposition grafts in the pig has shown a similar up-regulation of both MMP-2 and MMP-9 expression, again localized to the proliferative Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] smooth muscle cells at the base of the developing neointima. 9 5 In the mouse, Lijnen and co-workers 9 6 identi ed a dramatic increase in the level and activity of MMP-2 and MMP-9 following arterial injury and identi ed an association between uPA and plasminogen and neointima formation.
Further in vitro studies have shown that the activation of MMP-2 was crucial for the migration of vascular smooth muscle cells through a reconstituted basement membrane similar in composition to that surrounding the cells in vivo. 9 7 This has led to interest in the role of MT1-MMP, and further work in the rat carotid artery injury model showed a six-fold increase in MT1-MMP mRNA levels 3 days after injury. This coincided with an increase in activation of MMP-2 detected on gelatin zymography, while the total MMP-2 protein level reached a peak 5-7 days after injury. Similarly, MMP-9 overexpression by transfection of smooth muscle cells with a cDNA for rat MMP-9, increased cell migration in a collagen invasion assay and Boyden chamber in vitro. 9 8 Extending this work to animal models similarly increased cell migration and altered arterial remodelling.
Interestingly, transfection of vascular smooth muscle cells in culture with endothelial nitric oxide synthase gene inhibited cell migration, mediated by altered expression of MMPs. 9 9 A signi cant increase in the expression of TIMP-2 was observed, while the activity of both MMP-2 and MMP-9 was signi cantly reduced. The relevance of this to intimal hyperplasia in the human and the potential for therapeutic prevention is unclear.
In a primate model, positive immunostaining for MMP-1, -2, -3 and -9 appeared in the developing neointima throughout the rst week following balloon injury. 1 0 0 Early on, MMP-1, -3 and -9 were localized to replicating cells, and eventually con ned to the luminal surface of the neointima. MMP-2 positive cells appeared in the basal layer of the neointima 2 weeks post-injury and throughout the subsequent 4 weeks came to occupy the entire neointima. Matrix proteins surrounded these cells. This suggested a co-ordinated MMP response to the initial injury, but a later stage dependent upon MMP-2 for facilitating further migration but not proliferation of cells within the neointima. Evidence suggests that primate smooth muscle cell migration in vitro is regulated by PDGF and bFGF, with PDGF-induced migration dependent upon MMP-2 and bFGF actions dependent upon both MMP-2 and MMP-9. 1 0 1 Using human long saphenous vein in vitro, injury induced the expression of MMP-9, especially in the proliferative neointimal smooth muscle cells, and also increased the levels of both active and latent MMP-2. 1 0 2 In this model, intact vein developed a signi cantly thicker neointima than denuded vein. 1 0 3 Co-culture with an MMP inhibitor prevented neointimal formation in conjunction with a signicant decrease in the levels of MMP-2 and MMP-9. 1 0 4
Moons and co-workers demonstrated a signi cant increase in expression of MMP-3, -9, -12 and -13 in tandem with an increase in tPA and uPA expression within 15 days of allograft transplantation in mice, the period of active cellular migration predisposing to neointimal hyperplasia. 10 5 The role of TIMPs Models of intimal hyperplasia in which TIMP expression is increased have shown a reduction in neointimal formation.
Expression of TIMP-1 by the use of an adenoviral vector to transfect rat smooth muscle cells reduced intimal hyperplasia in the rat arterial injury model. 1 0 6 Interestingly, longer-term TIMP-1 overexpression led to excessive accumulation of cross-linked elastin. 1 0 7 Similar results were observed when 'wild-type' mice were compared with TIMP-1 de cient mice, where increased neointima was detected following electrical insult to the femoral artery in tandem with increased levels of MMP-2 and MMP-9 activity. 9 6 This has been studied in the human in vitro model of saphenous vein culture, where adenovirusmediated gene transfer of the human TIMP-1 gene inhibited smooth muscle cell migration and neointimal formation. 1 0 8 There was no effect upon cell proliferation or viability, and a speci c MMP inhibitory effect has been shown using in situ zymography.
TIMP-2 has been shown to have a dose-dependent effect in reducing cell proliferation and TIMP-3 promoted smooth muscle cell death by apoptosis. 2 5 These effects were independent of their inhibitory actions on MMPs and were not reproduced by the addition of synthetic MMP inhibitors. Clearly, this has implications for potential therapies based on TIMPs or gene therapy. In the human model, TIMP-1 and TIMP-2 secretion were increased in the early stages following injury, with TIMP-2 remaining partially attached to ECM. 1 0 9 TIMP-3 was detected before culture and expression was variable, detectable throughout periods in culture and remaining exclusively attached to the ECM. TIMP-4 expression was also increased following injury and reduced smooth muscle cell migration. 1 1 0 The regulation of TIMP expression seems to be an important net determinant of MMP activity in neointima formation, and appears to restrict it to the pericellular environment.
Summary
It is clear that smooth muscle cells can alter the surrounding matrix by the production and secretion of MMPs and their inhibitors, the balance of which regulates net matrix accumulation or destruction. Early after injury, migration into the intima seems to be the key step, initiating neointimal formation by proliferation and matrix synthesis. MMP inhibition seems to prevent this, but so far this is only established in animal models and in vitro culture of human vein. This may have major clinical implications for therapy directed at preventing intimal hyperplasia and reducing restenosis and graft failure, with the MMP/TIMP family representing an attractive target. However, the long-term ef cacy of therapy is a concern which will be discussed later in this review.
MMPs in atherosclerosis
MMPs may be involved in the early stages of plaque development. Central to the 'response to injury theory' of atherosclerosis are chronic endothelial injury and dysfunction, monocyte and leukocyte adhesion, and migration to the subintimal space followed by proliferation and ECM accumulation. 1 study by Pauly and colleagues, isolated rat vascular smooth muscle cells cultured on a gel of reconstituted basement membrane proteins secreted MMP-2, which was activated to degrade the proteins. 9 7 Antiserum against MMP-2 prevented migration through the basement membrane. Similar results have been observed in a rabbit model though direct evidence of an association in the human is lacking. 1 1 2 However, this appears to be the rst limiting step in atherogenesis controlled, at least in part, by MMPs.
Acute plaque disruption
Perhaps more importantly, there is increasing evidence to suggest that MMPs are intricately involved in the destruction of connective tissue prior to surface disruption and thrombo-embolism. The atherosclerotic plaque is a dynamic structure, undergoing continuous remodelling of the extracellular matrix upon which its structural integrity depends. Acute changes within the plaque, such as intraplaque haemorrhage, cap rupture and cap ulceration, are preludes to the onset of clinical ischaemic events ( Figure  2 ). 1 1 3 Previous studies have shown that the site of plaque rupture is characterized by an intense in ammatory in ltrate, 1 1 4 consisting predominantly of macrophages, foam cells and T-lymphocytes. It has been hypothesized that this in ammatory in ltration plays a key role in the destabilization of the plaque. 1 1 5 The in ltrate within the plaque undergoes a period of activation at the time of acute coronary syndromes, and the associated release of proteolytic enzymes may lead to destabilization of the plaque. 1 1 6 However, the events leading up to this activation remain unclear. There is a clear association between oxidized low-density lipoprotein (LDL) levels and atherosclerosis, possibly through a pro-in ammatory action as shown by a correlation between levels and severity of acute coronary syndromes and plaque macrophages. 1 1 7 Systemic changes in in ammatory markers have been reported, including white blood cell count and C-reactive protein. 1 1 8 ,1 1 9 Furthermore, C-reactive protein may be involved in the uptake of LDLs by macrophages. 1 2 0 The serum levels of anti-in ammatory cytokine IL-10, a cytokine which may be involved in the regulation of MMP activity in ischaemic tissue, 1 2 1 have been shown to be lower in patients with unstable angina. 1 2 2 The role of MMPs Early work by Vine and Powell demonstrated an increase in gelatinase activity in both occlusive and aneurysmal aortic disease compared with controls. 4 5 In atherosclerotic aortas, zymography suggested that this was predominantly MMP-9. They also demonstrated collagenase and stromelysin activity. Henney described the presence of MMP-3 mRNA in human coronary atheroma by in situ hybridization, localized to areas of intense macrophage in ltration in the shoulder of the plaque. 1 2 3 Subsequently, Galis and colleagues studied the expression of a variety of MMPs in human atherosclerotic plaques, and used in situ zymography to assess matrixdegrading activity. 1 2 4 In non-diseased arterial tissue, smooth muscle cells expressed MMP-2 as well as TIMP-1 and -2. In contrast, atherosclerotic lesions showed immunoreactivity for MMP-1, -2, -3 and -9 as well as the TIMPs, localizing MMP-1, -3 and -9 to macrophages, lymphocytes, smooth muscle cells and endothelial cells within the brous cap and shoulder of the plaque. In situ zymography demon- strated gelatinolytic and caseinolytic activity within the same areas, suggesting a potential role for these enzymes in plaque matrix degradation.
Further work on MMP-1 showed that expression in human carotid plaques retrieved following endarterectomy was predominantly by macrophages in the cap and shoulder regions, though subsets of smooth muscle cells and endothelial cells also expressed MMP-1. 1 2 5 A strong correlation was demonstrated between the percentage of the lipid core staining positively for MMP-1 and the percentage of core occupied by haemorrhage, a feature of plaque instability. More recently, work in a mouse model of accelerated atherosclerosis has suggested a protective effect of MMP-1 but the relevance of the observation in this model is unclear. 1 2 6 Brown and co-workers investigated the role of MMP-9 in acute coronary ischaemia. 1 2 7 They performed immunostaining for MMP-9 on atherectomy specimens retrieved from 12 patients with unstable angina and compared them to a similar cohort with stable angina. They reported positive staining in 85% of both groups. However, intracellular staining was seen in all of those with positive staining in the unstable angina group, compared with three of 10 of the stable group. The predominant cell types were identi ed as macrophages and smooth muscle cells. The authors reported this as evidence of active enzyme synthesis, since macrophages do not store MMP-9, though it does not prove cellular expression. 1 2 8 Though not truly quantitative, the study raised awareness of the potential role for MMP-9 in acute plaque disruption.
Further work supported the results of Brown and coworkers. McMillan et al showed that mRNA levels for MMP-9 were elevated in both occlusive and aneurysmal aortic tissue when compared with controls. 5 6 Thompson and colleagues provided some of the rst quantitative data regarding MMP-9 in aortic tissue, using ELISA to demonstrate a six-and tenfold increase in MMP-9 levels Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] in occlusive disease and aneurysmal disease respectively. Furthermore, while TIMP-1 levels were increased in aneurysmal tissue, occlusive aorta showed similar levels to controls, suggesting an imbalance between enzyme and inhibitor levels. 5 1 This did not, however, provide evidence of increased proteolysis or activity.
More recent work has clearly demonstrated an increase in the level and expression of MMP-9 in unstable carotid plaques based on symptomatology, spontaneous embolization and histological evidence of instability. 1 2 9 In a consecutive series of 75 patients undergoing carotid endarterectomy, the plaque level of MMP-9 was found to be four times higher in patients with recent symptoms. Expression was predominantly by macrophages around the necrotic core in the vulnerable regions of the plaque, particularly the shoulder and cap (Figure 3 ). There were no differences in TIMP-1 levels, suggesting an imbalance between proteolysis and inhibition.
There has been similar interest in the contribution of MMP-2 in more mature atherosclerotic lesions. Li and colleagues demonstrated an increase in the level and expression of MMP-2 in human atherosclerotic aortic tissue compared to non-diseased tissue. 1 3 0 They demonstrated increased MMP-2 activity and co-localized this to areas of macrophage in ltration, suggesting a possible role for MMP-2 in the development of the acute complications of atherosclerosis. This study was limited by the sample size of only 12 cases, collected from autopsies of trauma victims who were young, with no history of cardiovascular disease.
Understanding the role of MT1-MMP in the activation of MMP-2 led to a recent study of MT1-MMP expression and activation in atherosclerosis. 1 3 1 In normal vessels, MT1-MMP expression was detected in medial smooth muscle cells and to a lesser extent in the adventitia. In atheroma, MT1-MMP expression was found to co-localize with macrophages and smooth muscle cells. Cultured smooth muscle cells and macrophages were exposed to pro- Figure 3 Immunostain for MMP-9 in a plaque from a highly symptomatic patient, demonstrating intense staining in the shoulder and cap of the plaque, surrounding the necrotic core (3 50 magni cation). The level of MMP-9 in this study was found to be signi cantly higher in those patients with recent symptoms, evidence of spontaneous embolization from the plaque and histological features of plaque instability. 1 2 9 in ammatory cytokines IL-1a and TNF-a plus oxidized LDL. TNF-a stimulated a 3.8-fold increase in macrophage expression of MT1-MMP within 6 hours, whilst IL-1a , TNF-a and oxidized LDL exposure produced a two-to fourfold increase in expression and protein level by cultured smooth muscle cells in a time dependent-manner. While the response to cytokines in vitro was clear, the situation within the plaque in vivo is clearly more complex.
Further work has demonstrated the expression of other MMPs within atherosclerotic tissue, including the presence of MMP-7 and MMP-12 in human carotid lesions retrieved at endarterectomy. 1 3 2 
Evidence of an imbalance towards increased proteolysis in atherosclerosis
The presence and expression of MMPs within plaques does not necessarily confer an increased risk of plaque instability. However, an increase in proteolytic activity, or an imbalance between the levels of enzymes and their inhibitors, may lead to an overall increase in matrix degradation. Dif culty has arisen in investigating this concept since the preparation of tissue extracts, in which MMPs are separated from their substrate and inhibitors prior to assay, activates the gelatinases, preventing a true assessment of the in vivo state. 4 5 Evidence of an imbalance between MMPs and TIMPs has been provided by Knox and co-workers, who studied Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] proteolytic activity in aortic tissue from 25 patients with occlusive or aneurysmal disease and compared it to seven normal aortas. 5 4 They combined immunohistochemistry with in situ zymography to identify a net increase in proteolytic activity in excess of endogenous inhibition. 1 3 3 Occlusive and aneurysmal aorta demonstrated a marked increase in staining for MMP-1 and MMP-3 plus a smaller increase in TIMP-1. MMP-2 was also increased in the absence of an increase in TIMP-2. Whilst normal tissue failed to exhibit proteolytic activity, both disease subgroups demonstrated gelatinolytic and caseinolytic activity on their luminal aspect. Despite limitations of the in situ zymography technique, the study provided evidence of an imbalance between MMPs and their inhibitors, leading to a net increase in overall proteolysis.
Overexpression of TIMPs is likely to provide protection against plaque instability. Evidence for TIMPs counterbalancing the increase in MMP levels has been provided in rabbits. 1 3 4 Cholesterol fed animals developed atherosclerotic lesions that exhibited a two-to threefold increase in TIMP-1 and TIMP-2 levels. In situ zymography demonstrated excess MMP activity but in the areas of increased TIMP production this was less evident. Increased levels of TIMP-1 in mice have been shown to reduce the development of atherosclerotic lesions. 1 3 5 Apolipoprotein Ede cient mice, susceptible to developing accelerated atherosclerosis, subjected to adenovirus-mediated over-expression of TIMP-1 demonstrated a signi cant decrease in the size of lesions despite identical lipid and lipoprotein pro les. There was also a signi cant decrease in macrophage in ltration, MMP-2, MMP-3 and MMP-13 levels. Dietary lipid lowering has been shown to reduce macrophage in ltration and MMP-1 activity in the aortas of rabbits. 1 3 6 Aikawa et al demonstrated a decrease in activity of MMP-2, -3 and -9 in tandem with an increase in the collagen content of the vessel wall and increased accumulation of mature smooth muscle cells. 1 3 7 As discussed previously, TIMP-3 has some unique properties, the relevance of which is incompletely understood. When atherosclerotic lesions were compared with non-diseased tissue, TIMP-3 expression was vefold higher in the plaques. 1 3 8 This expression was co-localized to macrophages in the vulnerable areas of the plaque, in particular the cap and shoulder of the plaque, but also to a lesser extent medial smooth muscle cells. In contrast to isolated monocytes in vitro, macrophages expressed TIMP-3. Cultured vascular smooth muscle cells also expressed TIMP-3 along with TIMP-1 and -2, and this was up-regulated by the addition of PDGF and TGF-b in the absence of cellular proliferation. Clearly more work is required to study the speci c role of TIMP-3 within plaques. 2 4 More recently attempts have been made to associate the observed increase in proteolytic activity with evidence of plaque instability. Sukhova and colleagues provided evidence of increased collagenolysis in unstable carotid plaques. 1 3 9 They demonstrated co-localization of collagenase-cleaved collagen with macrophages expressing MMP-1 and MMP-13 in plaques, loss of type I collagen and increased collagenolysis. MMP-1 and MMP-13, the interstitial collagenases, are required for the initial step in collagen degradation, cleaving triple-helical brils of collagen types I, II and III at a single site, 1 4 0 producing fragments which are accessible to other proteolytic enzymes, in particular the gelatinases and stromelysins. Whilst the collection of tissue specimens was not standardized and the classi cation of tissue perhaps oversimpli ed, the study provided evidence of an association between enzyme levels and collagen degradation in plaques.
Systemic changes in MMP levels
A systemic factor that predicted vulnerable plaques would enable preventative intervention to be targeted at those most at risk. A number of systemic factors have been suggested, including C-reactive protein, IL-6 and TNF-a . 1 4 1 Work on MMPs has focused on the localized nature of the imbalance but one study measured peripheral blood levels of the gelatinases in patients with coronary disease. 1 4 2 The levels of MMP-2 and MMP-9 were measured by ELISA in 33 patients with acute coronary syndromes, 17 with stable angina and 17 normal control subjects. The level of MMP-2 in patients with stable angina was only slightly raised compared with controls, but those with acute coronary syndromes were twofold higher. This increase was sustained for 7 days after treatment. The level of MMP-9 was increased only in the acute coronary patients -twofold in patients with myocardial infarction and threefold in those with unstable angina -but the increase was only sustained for up to 3 days, returning to the control levels by day 7.
Work in patients undergoing carotid endarterectomy has shown a signi cant increase in circulating MMP-9 levels Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] in those patients with evidence of ongoing spontaneous particulate embolization. 1 4 3 This could either represent a systemic increase related to atherosclerotic in ammation or a re ection of the degree of cerebral injury. Cerebral injury in animals is associated with increased MMP expression and more recently similar evidence has been provided in human cardioembolic stroke. 1 4 4 White matter damage in vascular dementia has also been shown to be associated with increased MMP activity. 1 4 5 
Genetic factors
Genetic variations controlling MMP expression may predispose individuals to an imbalance between proteolysis and extracellular matrix accumulation. 6 Ye and colleagues have studied sequence variations in the MMP-3 gene, detecting a variant in the 59 -anking region of the gene promoter, arising from an insertion/deletion of an adenosine 1171 bp upstream from the start of transcription. 1 4 6 This resulted in a run of six adenosines (6A) in one allele and ve adenosines (5A) in the other. A total of 72 patients known to have coronary heart disease were genotyped and studied prospectively by angiography. The 6A/6A genotype was signi cantly associated with an increased progression of coronary atherosclerosis, with the 5A/6A demonstrating a slower progression. They hypothesized that the weaker promoter led to a reduction in MMP-3 leading to a net increase in matrix accumulation and disease progression. Clearly this is in contrast to any potential role in acute plaque disruption where the balance is tipped the other way. Subsequent work in vitro showed that the 5A allele had a twofold higher promoter activity than the 6A allele and thus may lead to less extracellular matrix accumulation and tip the balance in favour of degradation. 1 4 7 A study of 330 patients with myocardial infarction showed that the 5A/6A genotype was more common than in a control population (48.8% versus 32.7% respectively, p , 0.0001). 1 4 8 This was independent of all other cardiovascular risk factors, suggesting a possible genetic increase in susceptibility to plaque rupture.
Recent work has identi ed a further gene which, in combination with the functional 5A/6A polymorphism, increased susceptibility for intima-media thickening at the carotid bifurcation, namely an IL-6 gene functional G/C polymorphism in the promoter region. 1 4 9 The IL-6 polymorphism may represent a genetic predeterminant of increased in ammatory response.
More recently a polymorphism has been detected in the MMP-9 gene promoter, arising from a cytosine to thymidine transition at position -1562 relative to the start of transcription. 1 5 0 Transfection experiments and DNA-interaction assays showed that the thymidine allele had a higher promoter activity than the cytosine allele, probably related to the binding of a putative repressor protein to the cytosine residue. Genotype studies of 584 male patients following myocardial infarction showed a signi cant increase in the frequency of the thymidine allele in those patients with angiographic coronary stenoses of >50%, suggesting an association between this polymorphism and severity of disease.
Summary
Whilst many of the factors which predispose to the early development of the atherosclerotic lesion have been ident-i ed, there remains uncertainty as to the reasons why, after years of indolent growth, a plaque should suddenly undergo the acute changes which predispose to the onset of symptoms. There is mounting evidence associating increased levels and activity of MMPs within plaques and plaque instability. There are also convincing data to suggest an imbalance between MMP levels and their inhibitors, tipping the equilibrium from matrix accumulation towards increased matrix degradation. Such a localized increase has the potential to cause the acute plaque disruption, which precedes the onset of symptoms in both the coronary and cerebral circulations. MMPs represent an attractive target for pharmacotherapy to prevent plaque de-stabilization, and a variety of pharmaceutical agents have been shown to inhibit MMP activity. A true causal relationship will only be concluded from a formal randomized controlled trial of an MMP inhibitor in patients with signi cant carotid or coronary stenoses.
MMP inhibition
Most clinical and pre-clinical data regarding therapeutic manipulation of the ECM has been in the elds of arthritis, periodontal disease and cancer. 1 8 The hypotheses behind MMP inhibition are twofold: rst, that cellular migration is MMP-dependent, inhibition trapping the cell in its matrix surround; and secondly that an imbalance between enzymes and inhibitors leads to excessive tissue degradation as seen in aneurysms and unstable plaques. In this case inhibition may redress the balance back in favour of matrix accumulation. Potential methods of inhibition include: 1) increasing the level of TIMPs either by the exogenous administration of recombinant TIMPs or stimulating their local production through gene therapy 2) administration of synthetic inhibitors, either specically targeting MMPs or using compounds which affect MMP activity by a secondary mechanism to their intended use 3) reducing the production of MMPs.
TIMPs
Work on TIMPs has been restricted to animal models and in vitro culture of human vascular cells. Both TIMP-1 and TIMP-2 have been shown to inhibit tumour growth and metastasis in animals. 1 5 1 In vascular disease, as described previously, increased expression of TIMP-1 by rat smooth muscle cells reduced intimal hyperplasia, 1 0 6 and the TIMP-1 de cient mouse developed signi cantly more neointima after arterial injury than wild-type. 9 6 In vitro, adenovirusmediated gene transfer of the human TIMP-1 gene inhibited smooth muscle cell migration and neointimal formation. 1 0 8 Local overexpression of TIMP-1 by transfection of TIMP-1 DNA to smooth muscle cells in a rat model of aneurysmal disease prevented rupture 7 3 and increased levels of TIMP-1 in mice have been shown to reduce the development of atherosclerotic lesions. 1 3 5 Similarly, in an animal model of atherosclerosis, adenovirus-mediated overexpression of TIMP-1 led to a signi cant decrease in the size of atheromatous lesions despite identical lipid and lipoprotein proles. 1 3 5 More recently, local gene transfer of TIMP-2 in a mouse vein graft model decreased vascular re-modelling in tandem with a decrease in MMP activity. 1 5 2 Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] It is dif cult to extrapolate these data to potential applications in humans. The major drawback associated with TIMPs would be tissue delivery, since exogenous products would be metabolized and denatured with minimal tissue penetration at the intended site of action. Treatment would have to take the form of local tissue delivery or gene therapy. Cytokine stimulation of TIMPs would probably have signi cant side effects precluding clinical use.
Synthetic inhibitors
A number of synthetic inhibitors have been investigated, in particular speci c synthetic peptides, tetracycline-based antibiotics and anthracyclines. Synthetic peptides are largely analogues of the cleavage site in the collagen molecule with a metal-binding group in the position of the cleaved peptide bond. The metal binding group, usually a thiol, sulphydryl, carboxyl or hydroxamate group, binds to the zinc atom in the activity site of the MMP. 1 5 3 One of the rst synthetic peptides was batimastat, which has a broad-spectrum inhibitory action against the MMPs via a direct action. This showed promising results in the prevention of tumour development and metastasis in animal models 1 5 4 and has been tested in clinical trials, though the long-term use is precluded by its lack of oral bioavailability. 5 In aneurysmal disease, batimastat was shown to limit the expansion of abdominal aortic aneurysms. 1 5 5 This study employed the rat model of elastase infusion-induced aneurysm formation, and daily treatment with batimastat signi cantly reduced aortic dilatation compared with controls. Elastin preservation was observed accompanied by an attenuation of the in ammatory response.
Marimastat is a second-generation inhibitor with a similar structure and mode of action to batimastat. Unlike batimastat, marimastat is active orally. 1 5 6 Preliminary results in cancer patients were promising, though concerns were raised about signi cant musculoskeletal side effects in 30% of patients. 1 5 7 Marimastat has been studied in vascular models in vitro. Segments of human saphenous vein cultured with marimastat demonstrated a reduction in neointimal thickening. 1 0 4 This effect was paralleled by a signi cant reduction in MMP-2 and MMP-9 activity. Similar results were seen following angioplasty in the rat, where administration of a systemic MMP inhibitor similar to marimastat reduced the early migration of smooth muscle cells. 1 5 8 However, in this model there was a long-term 'catch-up' phenomenon because of increased smooth muscle cell proliferation. This is clearly a concern in the application of therapy to the human situation, suggesting MMP inhibition may simply delay but not prevent intimal hyperplasia. Marimastat treatment in a pig model of angioplastyinduced re-modelling also led to a signi cant reduction in luminal loss. 1 5 9 Studies utilizing the in vitro aneurysm model demonstrated that marimastat prevented the elastase-induced degradation of elastin in aortic tissue in vitro in parallel with a reduction in the level of activated MMP-2. 1 6 0 Further hydroxamate-based MMP inhibitors have been used to demonstrate suppression of experimental abdominal aortic aneurysms in the elastase-infusion rat model, 1 6 1 and also in chronic ow mediated arterial enlargement after the formation of arteriovenous stulae in rats. 1 6 2 Concerns about the long-term use of such compounds in view of their relatively broad spectrum and potential side effects have led to the development of more speci c inhibitors, 1 6 3 including orally acting speci c inhibitors of MMP-2 and MMP-9. 1 6 4 Results of their use, and other speci c synthetic inhibitors, in models of vascular disease are awaited with interest.
Tetracyclines
Doxycycline is a member of the tetracycline antibiotic family that, apart from its anti-bacterial action, is also a potent non-selective MMP inhibitor. Its main mode of action is through binding to the active zinc site, though it also binds to a non-active calcium site resulting in conformational change in the enzyme structure and loss of activity. 1 6 5 It may also suppress MMP expression. 1 6 6 Coupled with their low cost, clinical availability and good safety pro le, the tetracyclines are an attractive option in studies of MMP inhibition.
Most work in clinical trials has been in the eld of periodontal disease, where clinical improvement has been associated with a reduction in collagenase activity. 1 6 7 Oral administration of doxycycline in patients with osteoarthritis before hip surgery reduced collagenase and gelatinase activity in extracts of human cartilage, 1 6 8 con rming results from animal models. 1 6 9 Doxycycline treatment leads to a reduction in MMP-1 and MMP-13 production, possibly through a regulatory effect on cytokine and cytokine receptor synthesis. 1 7 0 Doxycycline has also been shown to reduce malignant cell proliferation and MMP-1 activity in a canine model of osteosarcoma. 1 7 1 In vitro, doxycycline has been shown to prevent intimal hyperplasia using an established human vein culture model, by inhibition of MMP activity (Figure 4 ). 1 7 2 This agent also prevented aneurysmal degeneration of the elastase-induced rat model of abdominal aortic aneurysm, causing elastin preservation associated with reduced MMP-9 activity. 1 7 3 Similar results have been obtained using chemically modied tetracyclines without antibiotic activity, compounds which may have even fewer side effects than doxycycline and no potential for encouraging bacterial resistance in long-term use. 1 7 4 
Figure 4
The effect of doxycycline in vitro on intimal hyperplasia. Segments of human long saphenous vein were cultured with increasing doses of doxycycline activity: (a) control; (b) and (c) represent increasing doses of doxycycline in culture. Doxycycline caused a dose-response reduction in intimal hyperplasia (see arrows), in tandem with reductions in MMP. 1 7 2 Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] In an in vitro model of aneurysmal disease, doxycycline prevented elastin degradation. 1 7 5 Intravenous tetracycline given to patients prior to aneurysm surgery showed rapid penetration of the arterial wall. 1 7 6 More importantly, patients who receive treatment preoperatively for 7 days with oral low-dose doxycycline exhibited a threefold reduction in the aortic wall expression of MMP-2 and a fourfold reduction in expression of MMP-9. 1 7 7 On the basis of these results the authors called for a prospective randomised controlled trial to assess the effect of long-term treatment on the expansion of small aneurysms.
Other inhibitory agents
Inhibition of MMP synthesis can be approached from the pharmacotherapy and experimental molecular standpoints. TGF-b , retinoids and corticosteroids have all been shown to down-regulate the expression of MMPs. However, their practical use in vivo is limited. For example, steroids have proved ineffective in preventing intimal hyperplasia, and though heparin has been shown to reduce expression of MMP-3 and MMP-9, it does not eliminate activity, nor prevent either atherosclerosis or intimal hyperplasia. 1 8 The alternative approach via application of antisense oligonucleotides to the MMP genes is possible but clinical application awaits a much more detailed study of the potential effects, both bene cial and harmful.
Targeting therapy at an earlier stage in the proteolytic cascade may prevent side effects associated with generalized MMP inhibition, and plasmin has been suggested as one such target. Guinea pig to rat xenografts, seeded with rat smooth muscle cells retrovirally transduced with the rat plasminogen activator inhibitor-1 gene, failed to develop aneurysms, exhibiting preservation of arterial elastin. 1 7 8 Control animals, lacking the transduced gene but with the vector alone or no seeding at all, developed aneurysms, the majority of which ruptured.
Other groups have targeted the in ammatory response within aneurysms including the inhibition of prostaglandin E2, which regulates the expression of MMP-9. Prostaglandin E2 has adverse effects upon smooth muscle cell viability and cytokine secretion in vitro, and indomethacin has been shown to reduce cytokine release and prostaglandin production in aortic explants. 1 7 9 Indomethacin, by reducing the synthesis of prostaglandin E2 also decreased the production of MMP-9 in the rat model of aneurysm development. 1 8 0 A case-control study of patients taking non-steroidal anti-in ammatory drugs demonstrated a lower rate of aneurysm growth rate compared with controls, suggesting a potentially effective treatment for preventing aneurysm expansion. 1 8 1 Other non-steroidal drugs have been shown to modulate MMP activity, though their action in vivo requires detailed clinical studies. 1 8 2 
HMG-CoA reductase inhibitors
There has been considerable interest in the bene cial effect exerted by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in patients with coronary and cerebrovascular disease, 1 8 3 which seems to be multifactorial. HMG-CoA reductase inhibitors have lipid-lowering effects, but also direct actions on vessel wall cell-cell interactions and MMP production, offering the exciting potential for modi cation of matrix regulation in vascular diseases.
A prospective study in patients with a history of myocardial infarction and elevated LDL cholesterol treated with uvastatin demonstrated a 32% reduction in stroke risk. 1 8 4 Also, uvastatin reduced the progression of angiographic coronary artery disease and event-free survival compared with placebo treatment. 1 8 5 Similar encouraging results have been obtained with other members of the statin family. 1 8 6 ,1 8 7 Using high resolution MRI techniques, signi cant plaque regression has been demonstrated following 12 months of treatment with simvastatin. 1 8 8 Initially thought to be secondary to a lipid-lowering effect, the effect of statins appears to be more complex. 1 8 9 Two members of the group, uvastatin and simvastatin, have been shown to inhibit smooth muscle cell migration and proliferation independent of their lipid-lowering activity. 1 9 0 Further work by the same group suggested a direct anti-proliferative effect upon the arterial wall 1 9 1 and uvastatin treatment in a rat model of intimal hyperplasia prevented neointima formation in this way. 1 9 2 In vitro work has shown that HMG CoA reductase inhibitors directly interfered with the adherence of monocytes to endothelium by reducing the expression of monocyte cell surface receptors, again independent of their lipid-lowering effect. 1 9 3 This has also been shown in parallel with a down-regulation in P-selectin expression on endothelial cells. 1 9 4 Moreover, both uvastatin and simvastatin inhibit macrophage secretion of MMP-9 in vitro. 1 9 5 Simvastatin has been shown to exert anti-in ammatory and cardio-protective effects in apolipoprotein-E de cient mice. 1 9 6 Cerivastatin suppressed the growth of macrophages in rabbits 1 9 7 while uvastatin and pravastatin reduced MMP-1, -3 and -9 expression in a similar model with preservation of collagen. 1 9 8 Pravastatin treatment prior to carotid endarterectomy reduced plaque lipid content, in ammation, MMP activity and cell death in tandem with an increase in collagen content. 1 9 9 Statin treatment has been shown in two separate studies to confer a signi cant and lipidindependent reduction in CRP levels associated with the severity of atherosclerosis. 2 0 0 ,2 0 1 Vascular Medicine 2002; 7: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] Summary A broad spectrum of therapeutic agents has the potential to modify the proteolytic effect of MMPs in vascular disease, both at the level of expression and secretion, and also by reducing activity. Much of the evidence comes from in vitro and animal work, though some of these agents have been shown to be bene cial in human studies. Further work is required to clarify the nature of the bene t and potential long-term side effects, particularly with tetracyclines and selective synthetic MMP inhibitors.
